Metabolic Reprogramming and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Mechanisms and Therapeutic Strategies
Anticancer Research · 2026-07 · 46 (7) · 3599-3608
DOI: 10.21873/anticanres.18226 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Dohee Ahn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Metabolic Reprogramming, Drug Resistance, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea.
- Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea kchoi@cbu.ac.kr.
Zitieren
APA
Ahn, D., & Choi, K. C. (2026). Metabolic Reprogramming and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Mechanisms and Therapeutic Strategies. Anticancer Research, 46(7), 3599-3608. https://doi.org/10.21873/anticanres.18226
Vancouver
Ahn D, Choi KC. Metabolic Reprogramming and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Mechanisms and Therapeutic Strategies. Anticancer Research. 2026;46(7):3599-3608. doi:10.21873/anticanres.18226
BibTeX
@article{Ahn2026,
author = {Ahn, Dohee and Choi, Kyung-Chul},
title = {Metabolic Reprogramming and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Mechanisms and Therapeutic Strategies},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {7},
pages = {3599--3608},
doi = {10.21873/anticanres.18226}
}
EUVIMED